Skip to main content
Erschienen in: Tumor Biology 1/2011

01.02.2011 | Research Article

Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies

verfasst von: Vilma Oliveira Frick, Claudia Rubie, Pirus Ghadjar, Sabrina K. Faust, Mathias Wagner, Stefan Gräber, Martin K. Schilling

Erschienen in: Tumor Biology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Chemokines have been proposed to contribute to tumour growth and metastatic spread of several cancer entities. Here, we examined the relative levels of CXCL12/CXCR4 in resection specimens from patients with different malignant and non-malignant colorectal diseases as well as colorectal liver metastases (CRLM). CXCL12/CXCR4 mRNA and protein expression profiles were assessed by quantitative real-time PCR, Western blot analysis, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry in resection specimens from patients with ulcerative colitis (UC; n = 15), colorectal adenoma (CRA; n = 15), colorectal adenocarcinoma (CRC; n = 47) and CRLM (n = 16). Corresponding non-affected tissues served as control. In contrast to UC tissues, CXCL12 showed a distinct down-regulation in CRA, CRC and CRLM specimens, whereas the corresponding receptor CXCR4 demonstrated a significant up-regulation in CRC and CRLM related to corresponding non-affected tissues (p < 0.05, respectively). Our results strongly suggest an association between CXCL12/CXCR4 expression and the induction of CRA, CRC and the development of CRLM. Therefore, CXCR4 may be a potential target for specific therapeutic interventions.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43–66.CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43–66.CrossRefPubMed
2.
Zurück zum Zitat Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249:87–96.CrossRefPubMed Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249:87–96.CrossRefPubMed
3.
Zurück zum Zitat McLeod HL, McKay JA, Collie-Duguid ESR, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer. 2000;36:1706–12.CrossRefPubMed McLeod HL, McKay JA, Collie-Duguid ESR, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer. 2000;36:1706–12.CrossRefPubMed
4.
Zurück zum Zitat Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524–36.CrossRefPubMed Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524–36.CrossRefPubMed
5.
Zurück zum Zitat Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.CrossRefPubMed Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.CrossRefPubMed
6.
Zurück zum Zitat Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2004;410:50–6.CrossRef Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2004;410:50–6.CrossRef
7.
Zurück zum Zitat Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002;86:1250–6.CrossRefPubMed Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002;86:1250–6.CrossRefPubMed
8.
Zurück zum Zitat Voermans C, van Heese WP, De Jong I, Gerritsen WR, van Der Schoot CE. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia. 2002;16:650–7.CrossRefPubMed Voermans C, van Heese WP, De Jong I, Gerritsen WR, van Der Schoot CE. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia. 2002;16:650–7.CrossRefPubMed
9.
Zurück zum Zitat Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832–7.PubMed Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832–7.PubMed
10.
Zurück zum Zitat Rubie C, Kollmar O, Frick VO, Wagner M, Brittner B, Gräber S, et al. Differential CXC receptor expression in colorectal carcinomas. Scand J Immunol. 2008;68:635–44.PubMed Rubie C, Kollmar O, Frick VO, Wagner M, Brittner B, Gräber S, et al. Differential CXC receptor expression in colorectal carcinomas. Scand J Immunol. 2008;68:635–44.PubMed
11.
Zurück zum Zitat Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR4, a chemokine receptor is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol. 1998;69:99–104.CrossRefPubMed Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR4, a chemokine receptor is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol. 1998;69:99–104.CrossRefPubMed
12.
Zurück zum Zitat Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsujy S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–5.PubMed Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsujy S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–5.PubMed
13.
Zurück zum Zitat Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a novel therapeutic approach for Non-Hodgkin’s lymphoma. Cancer Res. 2002;62:3106–12.PubMed Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a novel therapeutic approach for Non-Hodgkin’s lymphoma. Cancer Res. 2002;62:3106–12.PubMed
14.
Zurück zum Zitat Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor –1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung metastases. Am J Respir Crit Care Med. 2003;167:1667–86.CrossRef Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor –1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung metastases. Am J Respir Crit Care Med. 2003;167:1667–86.CrossRef
15.
Zurück zum Zitat Schimanski CC, Galle PR, Moehler M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol. 2008;14:4721–4.CrossRefPubMed Schimanski CC, Galle PR, Moehler M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol. 2008;14:4721–4.CrossRefPubMed
16.
Zurück zum Zitat Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744–53.CrossRefPubMed Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744–53.CrossRefPubMed
17.
Zurück zum Zitat Wang SC, Lin JK, Wang HS, Yang SH, Fen-Yau Li A, Chang SC. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis. 2010;25:1185–91.CrossRefPubMed Wang SC, Lin JK, Wang HS, Yang SH, Fen-Yau Li A, Chang SC. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis. 2010;25:1185–91.CrossRefPubMed
18.
Zurück zum Zitat Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Ichikawa K, et al. Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer. 2008;98:1682–9.CrossRefPubMed Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Ichikawa K, et al. Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer. 2008;98:1682–9.CrossRefPubMed
19.
Zurück zum Zitat Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19–22.CrossRefPubMed Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19–22.CrossRefPubMed
20.
Zurück zum Zitat Bustin SA. Absolute quantification of mRNA using real time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169–93.CrossRefPubMed Bustin SA. Absolute quantification of mRNA using real time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169–93.CrossRefPubMed
21.
Zurück zum Zitat Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes. 2005;19:101–9.CrossRefPubMed Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes. 2005;19:101–9.CrossRefPubMed
22.
Zurück zum Zitat Schoonjans F, Zalata A, Depuydt CE, Comhaire FH. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995;48:257–62.CrossRefPubMed Schoonjans F, Zalata A, Depuydt CE, Comhaire FH. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995;48:257–62.CrossRefPubMed
23.
Zurück zum Zitat Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia. 2007;9:862–70.CrossRefPubMed Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia. 2007;9:862–70.CrossRefPubMed
24.
Zurück zum Zitat Kollmar O, Rupertus K, Scheuer C, Nickels RM, Haberl GCY, Tilton B, et al. CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer. 2010;126:1302–15.PubMed Kollmar O, Rupertus K, Scheuer C, Nickels RM, Haberl GCY, Tilton B, et al. CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer. 2010;126:1302–15.PubMed
25.
Zurück zum Zitat Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Morija Y, Kanai Y, Hirohashi S. Prognosticsignificance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol. 2009;132:202–10.CrossRefPubMed Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Morija Y, Kanai Y, Hirohashi S. Prognosticsignificance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol. 2009;132:202–10.CrossRefPubMed
26.
Zurück zum Zitat Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11:651–61.PubMed Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11:651–61.PubMed
27.
Zurück zum Zitat Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.CrossRefPubMed Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.CrossRefPubMed
28.
Zurück zum Zitat Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, et al. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J Gastroenterol. 2006;12:6627–33.PubMed Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, et al. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J Gastroenterol. 2006;12:6627–33.PubMed
29.
Zurück zum Zitat Ottaiano A, di Palma A, Napoletano M, Pisano C, Pignata S, Tatangelo F, et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother. 2005;54:781–91.CrossRefPubMed Ottaiano A, di Palma A, Napoletano M, Pisano C, Pignata S, Tatangelo F, et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother. 2005;54:781–91.CrossRefPubMed
30.
Zurück zum Zitat Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, et al. Effect of chemokine receptor CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–50.CrossRefPubMed Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, et al. Effect of chemokine receptor CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–50.CrossRefPubMed
31.
Zurück zum Zitat Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.CrossRefPubMed Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.CrossRefPubMed
32.
Zurück zum Zitat Garber K. First results for agents targeting cancer-related inflammation. J Natl Cancer Inst. 2009;101:1110–2.CrossRefPubMed Garber K. First results for agents targeting cancer-related inflammation. J Natl Cancer Inst. 2009;101:1110–2.CrossRefPubMed
Metadaten
Titel
Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies
verfasst von
Vilma Oliveira Frick
Claudia Rubie
Pirus Ghadjar
Sabrina K. Faust
Mathias Wagner
Stefan Gräber
Martin K. Schilling
Publikationsdatum
01.02.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0112-y

Weitere Artikel der Ausgabe 1/2011

Tumor Biology 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.